0000000001258118
AUTHOR
F. Vaccaro
Cyclosporine A + Glybenclamide. Effect on Glucose Metabolism: Preliminary Results
Cyclosporine A (CsA) is an immunosuppressive drug which determines, at high dosage, glucose intolerance (1). Different drugs present a pharmacological interaction with CsA increasing or reducing its blood level (2). To investigate the role of Glybenclamide (HB419), a sulphonilureic oral antidiabetic drug of large use, on CsA glucose metabolic effect, we have administered CsA + HB419 in rats. The aim of our work is to evaluate if HB419 influences CsA blood levels and if it improves glucose tolerance.
Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease
Background: In end-stage renal disease, fetuin-A has been demonstrated to be reduced and inversely related to cardiovascular mortality. This study had 2 distinct aims. The first was to verify if circulating concentration of fetuin-A may depend on renal function in patients with chronic kidney disease (CKD). Furthermore, we analyzed the correlation of fetuin-A with the biomarker of endothelial dysfunction endothelin-1 (ET-1), and with the inflammatory cytokine interleukin-6 (IL-6). Methods: In 108 subjects with stage 3-5 CKD, plasma levels of fetuin-A, ET-1 and IL-6 were assayed. Patients were studied first as a whole group and then were divided according to stages of CKD and fetuin-A tertil…